Tony et al. suggested that IGF2BP1 functions as a novel potential target to inhibit proliferation and induce apoptosis, partially by downregulating c-MYC mRNA and Ki-67 protein levels during HCC treatment [41]. The gene discussed is IGF2BP1; the disease is hepatocellular carcinoma.